Tools
Tools
Pomara, N and Bruno, D (2018) Pathological increases in neuronal hyperactivity in selective cholinergic and noradrenergic pathways may limit the efficacy of Aβ-based interventions in MCI and Alzheimer’s disease. Journal of Alzheimer's Disease Reports, 2 (1). pp. 165-167. ISSN 2542-4823
|
Text
adr_2018_2-1_adr-2-1-adr180077_adr-2-adr180077.pdf - Published Version Available under License Creative Commons Attribution Non-commercial. Download (46kB) | Preview |
Abstract
In spite of compelling evidence linking Aβ disturbances to the pathophysiology of Alzheimer’s disease, Aβ based treatments have consistently failed to produce any beneficial effects both in mild cognitive impairment (MCI) and Alzheimer’s disease (AD) even with successful reductions of toxic aggregated and soluble Aβ species. Before abandoning both the hypothesis and approach, there is a need to examine some overlooked factors that may have contributed to the lack of efficacy, such as the potential druginduced increases in neuronal hyperactivity leading to adverse cognitive effects. In particular, we posit that selective cholinergic and noradrenergic pathways will be especially vulnerable to this adverse effect. If confirmed, this idea could help identify a potentially preventable and treatable obstacle for enhancing the efficacy of therapeutic agents in MCI and AD.
| Item Type: | Article |
|---|---|
| Subjects: | B Philosophy. Psychology. Religion > BF Psychology R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry R Medicine > RM Therapeutics. Pharmacology |
| Divisions: | Natural Sciences & Psychology (closed 31 Aug 19) |
| Publisher: | IOS Press |
| Date Deposited: | 10 Sep 2018 09:17 |
| Last Modified: | 04 Sep 2021 10:08 |
| DOI or ID number: | 10.3233/ADR-180077 |
| URI: | https://researchonline.ljmu.ac.uk/id/eprint/9177 |
 |
View Item |